Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson's Disease And Motor Fluctuations

NCT02224664 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02224664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02224664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson's Disease And Motor Fluctuations
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
March 31, 2016
Enrollment
50 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease